Q2 2025 TG Therapeutics Inc Earnings Call Transcript
Key Points
- TG Therapeutics Inc (TGTX) reported strong financial performance with total revenue of $141.1 million for Q2 2025, marking a 91% increase compared to the same period last year.
- BRIUMVI, the company's flagship product, continues to gain momentum with US net sales totaling approximately $139 million in Q2, exceeding internal expectations.
- The company is expanding its market presence with nearly one-third of new IV anti-CD20 patients being prescribed BRIUMVI.
- TG Therapeutics Inc (TGTX) is developing a subcutaneous version of BRIUMVI, which could significantly expand its addressable market by appealing to patients who prefer self-administered options.
- The company has a strong capital position with approximately $279 million in cash, cash equivalents, and investment securities, enabling continued execution on long-term strategies.
- Operating expenses increased to approximately $71 million in Q2 2025, up from $46.9 million in Q2 2024, primarily due to ongoing R&D investments.
- The company anticipates some quarter-to-quarter variability in expenses related to the development of subcutaneous BRIUMVI.
- There is a potential risk of payer push for lower-cost at-home therapies, which could impact the demand for IV formulations.
- The company did not provide specific Q3 guidance, which may create uncertainty about short-term financial performance.
- The development and approval timeline for subcutaneous BRIUMVI is lengthy, with anticipated enrollment completion in 2026 and potential market launch in 2028.
Greetings. Welcome to TG Therapeutics' second quarter earnings call and Webcast. (Operator Instructions) Please note, this conference is being recorded.
At this time, I'll turn the conference call over to Jenna Bosco, Chief Communications Officer. Jenna, you may now begin.
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the second quarter 2025 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercial Officer; and Sean Power, our Chief Financial Officer.
Following our safe harbor statement, Mike will provide an overview of our recent corporate development. Adam will share an update on our commercial efforts and Sean will give a summary of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I would like to remind everyone that we will be making forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
